PRX-102

BIOLOGICAL4 trials

Sponsors

Protalix, Protalix Ltd

Conditions

Fabry DiseaseFabry disease lysosomal storage disease

Phase 1

Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

CompletedNCT01678898

ProtalixFabry Disease

Start: 2012-10-31End: 2016-03-06Updated: 2023-09-13

Phase 3

Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease

WithdrawnNCT02921620

ProtalixFabry Disease

Start: 2017-07-31End: 2018-07-31Updated: 2018-01-08

A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase Beta

Active, not recruitingNL-OMON45301

Protalix LtdFabry disease lysosomal storage disease

Start: 2017-10-05Target: 5Updated: 2024-02-28

An Open Label Study of the Safety and Efficacy of PRX 102 in Patients with Fabry Disease Currently Treated With REPLAGAL® (Agalsidase alfa)

Active, not recruitingNL-OMON47873

Protalix LtdFabry disease lysosomal storage disease

Start: 2018-08-07Target: 5Updated: 2024-02-28